Extend control with VABYSMO®

Deliver vision gains and early anatomical improvements while extending over 60% of patients to 16-week treatment intervals*3,4,14,20

In 63% of nAMD patients with evaluable data at Week 112 in VABYSMO 6.0 mg up to Q16W arm in TENAYA/LUCERNE pooled. In 62% of DME patients with evaluable data at Week 96 in VABYSMO 6.0 mg up to Q16W arm in YOSEMITE/RHINE pooled.

Current IVT treatments that target the VEGF pathway alone require frequent injections to maintain vision gains and anatomical improvements5-8


Need anti-VEGF IVT as frequently as every 4-8 weeks, resulting in high patient and clinic burden5-8*

*After 1 year of treatment. Studies included patients treated with IVT injections of ranibizumab and aflibercept.



Targeting Ang-2 along with VEGF-A can improve control of nAMD and DME9-12


Ang-2 amplifies damage from VEGF-A and drives vascular instability9-12






    Study Design

    Study Design


Roche Pharmaceuticals (Israel) Ltd.

6 Hacharash St. Hod Hasharon
Telephone: 09-9737777
E-mail: israel.ophthalmology@roche.com




Neovascular (wet) age-related macular degeneration

Diabetic macular edema

Additional Information and Materials

Israeli Experts Sharing Experience

Learn More>>

VABYSMO® is approved is Israel

Download Registration letter

VABYSMO® Administration Guide

Learn More>>

VABYSMO® Prescription Information

Read on MoH website>>

New Angle In Retinal Diseases

Learn More>>

The bispecific antibody for treatment of retinal diseases

Dr. Itay Magal

Learn More>>

"Eye-Know" Website for patients and Care givers

Click here>>

Ophthalmology Team Israel



Tehila Levy Talmi

Therapeutic Area Lead




Nadia Lander

Patient Journey Partner




Hila Tzeruya

Global Surgical Device Liaison Ophthalmology (GSDL)




Shani Potesman Yona

Medical Manager




Tseela Naim

Patient Journey Partner




Maytal Rabinovitch

Patient Journey Partner




Orly Margolin Chen

Patient Journey Partner




Hadar Zalmanovitch

Patient Journey Partner


  • List of abbreviations
    • AEs: adverse events
    • AMD: age-related macular degeneration
    • Ang-2: angiopoietin-2
    • APTC: Anti-Platelet Trialists’ Collaboration
    • BCVA: best corrected visual acuity
    • CNV: choroidal neovascularisation
    • CST: central subfield thickness
    • DME: diabetic macular oedema
    • DR: diabetic retinopathy
    • DRSS: diabetic retinopathy severity scale
    • ETDRS: early treatment diabetic retinopathy study
    • ETDRS-DRSS: early treatment diabetic retinopathy study diabetic retinopathy severity scale
    • Fc: fragment crystallisable
    • FFA: fundus fluorescein angiography
    • HbA1c: glycated haemoglobin
    • IOI: intraocular inflammation
    • ILM: inner limiting membrane
    • ILM-RPE: inner limiting membrane-retinal pigment epithelium
    • IRF: intraretinal fluid
    • IVT: intravitreal
    • nAMD: neovascular age-related macular degeneration
    • NPDR: non-proliferative diabetic retinopathy
    • PDR: proliferative diabetic retinopathy
    • RAP: retinal angiomatous proliferation
    • RPE: retinal pigment epithelium
    • SAE: serious adverse events
    • SD: standard deviation
    • SRF: subretinal fluid
    • VEGF: vascular endothelial growth factor
    • VEGF-A: vascular endothelial growth factor-A


  • References

     1. Heier JS, et al. Lancet. 2022;399(10326):729-40.

     2. Wykoff CC, et al. Lancet. 2022;399(10326):741-755.

     3. Holz FG, et al. Presented at EURETINA 2022, Hamburg, Germany, 1–4 September 2022. 

     4. Schlottmann PG, et al. Presented at EURETINA 2022, Hamburg, Germany, 1–4 September 2022. 

     5. Ciulla TA, et al. Ophthalmol Retina. 2020;4(1):19–30.

     6. Skelly A, et al. Vision (Basel). 2019;3:41.

     7. DeCroos FC, et al. Am J Ophthalmol. 2017;180:142–50.

     8. Ciulla TA, et al. Br J Ophthalmol. 2021;105(2):216–221.

     9. Heier JS, et al. Retina. 2021;41(1):1–19.

    10. Regula JT, et al. EMBO Mol Med. 2016;8:1265–88.

    11. Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635–661.

    12. Joussen AM, et al. Eye. 2021;35:1305–1316.

    13. Khanani AM, et al. Ophthalmol Sci. 2021;1(4):100076. 

    14. Priglinger SG, et al. Presented at the Macula Society 45th Annual Meeting, Berlin, Germany, June 8–11, 2022.

    15. Data on File. nAMD. Change from Baseline in CST. October 2020.

    16. Data on File. nAMD. Summary of Clinical Safety. June 2022.

    17. Eter N, et al. Ophthalmol Sci. 2022;2(1):100111.

    18. Heier JS, et al. Presented at the Annual Meeting of the American Academy of Ophthalmology Retina Subspecialty Day 2021, New Orleans, LA, November 12–13, 2021.

    19. Data on File. DME. Change from Baseline in CST. November 2021. 

    20. Baumal CR, et al. Presented at the Association for Research in Vision and Ophthalmology, Denver, CO, May 1–4, 2022.

    21. Data on File. DME. Summary of Clinical Safety. February 2022.

    22. Figueroa MS, et al. Presented at the 22nd EURETINA Congress, Hamburg, Germany, September 1–4, 2022.

    23. Data on File. nAMD. Patient Case. September 2022.

    24. Data on File. DME. Patient Case. September 2022.

    25. Roche Data on File


Do you have general questions? Feel free to  contact us.

Roche Pharmaceuticals (Israel) Ltd.

6 Hacharash St. Hod Hasharon
Telephone: 09-9737777
E-mail: israel.ophthalmology@roche.com